AT1965, an inhibitor of CMTR2 that is currently in clinical trials (NCT06234098), activates B cell-mediated immune responses in a lung cancer model and shows synergistic antitumor effects when combined with PD-1 inhibition62. Here, CMTR2 is linked to lung carcinoma.